keyword
MENU ▼
Read by QxMD icon Read
search

Glivec

keyword
https://www.readbyqxmd.com/read/27916045/-a-comparison-of-efficacy-and-safety-between-chinese-generic-imatinib-versus-branded-imatinib-in-patients-with-newly-diagnosed-chronic-myeloid-leukemia-in-the-chronic-phase-a-single-center-prospective-cohort-study
#1
H X Shi, Y Z Qin, Y Y Lai, X J Huang, Q Jiang
Objective: To compare the efficacy and safety between Chinese generic imatinib (Xinwei(®), Jiansu Hansoh Pharmaceutical Group Co., Ltd.) versus branded imatinib (Glivec(®), Novartis) in patients with newly-diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Methods: Patients with newly diagnosed CML-CP were enrolled and assigned to receive either Xinwei or Glivec at an initial dose of 400 mg/d according to patients' financial capability. The efficacy and adverse effects were evaluated. Results: From January 2014 to September 2015, 145 eligible patients were assigned to Xinwei (n=89) or Glivec (n=56) group...
December 1, 2016: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/27535853/-the-impact-of-glivec-related-side-effects-on-daily-life-in-chinese-patients-with-chronic-myeloid-leukemia-in-the-chronic-phase
#2
L Yu, H B Wang, X J Huang, Q Jiang
OBJECTIVE: To explore the impact of Glivec related side effects on daily life in Chinese patients with chronic myeloid leukemia (CML) in the chronic phase (CP). METHODS: From May to November in 2014, anonymous questionnaires were distributed to adult CML patients who were receiving tyrosine kinase inhibitors (TKI) treatment in China. The impact of TKI related side effects on daily life were assessed by the score of 1 (no impact) to 5 (high impact) from patient self- report...
July 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27238737/shooting-for-the-moon-or-flying-too-near-the-sun-crossing-the-value-rubicon-in-precision-cancer-care
#3
Mark Lawler, Declan French, Raymond Henderson, Ajay Aggarwal, Richard Sullivan
In his last two State of the Union addresses, President Barack Obama has focused on the need to deliver innovative solutions to improve human health, through the Precision Medicine Initiative in 2015 and the recently announced Cancer Moonshot in 2016. Precision cancer care has delivered clear patient benefit, but even for high-impact medicines such as imatinib mesylate (Glivec) in chronic myeloid leukaemia, the excitement at the success of this practice-changing clinical intervention has been somewhat tempered by the escalating price of this 'poster child' for precision cancer medicine (PCM)...
2016: Public Health Genomics
https://www.readbyqxmd.com/read/27169704/impact-of-orphan-drugs-on-latvian-budget
#4
Konstantins Logviss, Dainis Krievins, Santa Purvina
BACKGROUND: Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. METHODS: Our study covered a 5-year period, from 2010 to 2014...
2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27050374/identification-of-galectin-1-as-a-novel-mediator-for-chemoresistance-in-chronic-myeloid-leukemia-cells
#5
Wu Luo, Li Song, Xi-Lei Chen, Xiang-Feng Zeng, Jian-Zhang Wu, Cai-Rong Zhu, Tao Huang, Xiang-Peng Tan, Xiao-Mian Lin, Qi Yang, Ji-Zhong Wang, Xiao-Kun Li, Xiao-Ping Wu
Multidrug resistance protein-1 (MDR1) has been proven to be associated with the development of chemoresistance to imatinib (Glivec, STI571) which displays high efficacy in treatment of BCR-ABL-positive chronic myelogenous leukemia (CML). However, the possible mechanisms of MDR1 modulation in the process of the resistance development remain to be defined. Herein, galectin-1 was identified as a candidate modulator of MDR1 by proteomic analysis of a model system of leukemia cell lines with a gradual increase of MDR1 expression and drug resistance...
May 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/27030078/immunological-off-target-effects-of-imatinib
#6
REVIEW
Laurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, Maha Ayyoub, Guido Kroemer
Around 15 years ago, imatinib mesylate (Gleevec(®) or Glivec(®), Novartis, Switzerland) became the very first 'targeted' anticancer drug to be clinically approved. This drug constitutes the quintessential example of a successful precision medicine that has truly changed the fate of patients with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours by targeting the oncogenic drivers of these diseases, BCR-ABL1 and KIT and/or PDGFR, mutations in which lead to gain of function of tyrosine kinase activities...
July 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/26826644/submolecular-regulation-of-cell-transformation-by-deuterium-depleting-water-exchange-reactions-in-the-tricarboxylic-acid-substrate-cycle
#7
László G Boros, Dominic P D'Agostino, Howard E Katz, Justine P Roth, Emmanuelle J Meuillet, Gábor Somlyai
The naturally occurring isotope of hydrogen ((1)H), deuterium ((2)H), could have an important biological role. Deuterium depleted water delays tumor progression in mice, dogs, cats and humans. Hydratase enzymes of the tricarboxylic acid (TCA) cycle control cell growth and deplete deuterium from redox cofactors, fatty acids and DNA, which undergo hydride ion and hydrogen atom transfer reactions. A model is proposed that emphasizes the terminal complex of mitochondrial electron transport chain reducing molecular oxygen to deuterium depleted water (DDW); this affects gluconeogenesis as well as fatty acid oxidation...
February 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/26721343/imatinib-reduces-cholesterol-uptake-and-matrix-metalloproteinase-activity-in-human-thp-1-macrophages
#8
Jelena Gacic, Emina Vorkapic, Renate Slind Olsen, Daniel Söderberg, Therese Gustafsson, Robert Geffers, Karin Skoglund, Andreas Matussek, Dick Wågsäter
BACKGROUND: Imatinib mesylate (Glivec®, formerly STI-571) is a selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. However, there are reports suggesting that imatinib could be atheroprotective by lowering plasma low-density lipoprotein (LDL). AIM: To investigate the potential inhibitory effect of imatinib on cholesterol uptake in human macrophages as well as its effect on matrix metalloproteinase (MMP) activity...
February 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/26189684/diagnosis-and-treatment-of-dermatofibrosarcoma-protuberans-european-consensus-based-interdisciplinary-guideline
#9
Philippe Saiag, Jean-Jacques Grob, Celeste Lebbe, Josep Malvehy, Veronique del Marmol, Hubert Pehamberger, Ketty Peris, Alexander Stratigos, Mark Middelton, Lars Basholt, Alessandro Testori, Claus Garbe
Dermatofibrosarcoma protuberans (DFSP) is a skin fibroblastic tumour that is locally aggressive, with a tendency for local recurrence, but rarely metastasizes. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on DFSP diagnosis and treatment, based on systematic literature reviews and the experts' experience...
November 2015: European Journal of Cancer
https://www.readbyqxmd.com/read/25757922/comparative-study-of-the-anti-leukemic-effects-of-imatinib-mesylate-glivec%C3%A2-tablet-and-its-generic-formulation-ohk9511
#10
COMPARATIVE STUDY
Masako Yokoo, Yasushi Kubota, Yoko Tabe, Shinya Kimura
Long-term treatment with imatinib mesylate (IM) allows patients with chronic myeloid leukemia (CML) to live a near-normal lifespan. However, the fact that tyrosine kinase inhibitors, including IM, are extremely expensive is a major cause of poor adherence, resulting in disease relapse or drug resistance. Therefore, physicians are encouraged to prescribe generic drugs to reduce the financial burden of medical expenses. In Japan, only generic drugs that have a basic chemical structure and pharmacokinetic data that are the same as those of the original drug are approved...
2015: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/25644376/generic-imatinib-in-the-treatment-of-chronic-myeloid-leukemia-cerrahpa%C3%A5-a-experience
#11
COMMENT
Ahmet Emre Eskazan, Teoman Soysal
As the first tyrosine kinase inhibitor (TKI), imatinib (Gleevec or Glivec, Novartis Pharmaceuticals) was introduced, the treatment of chronic myeloid leukemia (CML) has changed radically, and the TKIs are now the mainstay of CML treatment. The substantially high treatment cost has unfortunately been a major issue, which puts a strain on health-care budgets even in developed countries. So reimbursement policies encourage generic drug (i.e. generic imatinib) use to lower the expenses, and it is true that generics would lead to considerable cost savings, but they also give rise to questions associated with their efficacy, safety and quality...
April 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/25572603/sphincter-sparing-resection-of-a-large-obstructive-distal-rectal-gastrointestinal-stromal-tumour-after-neoadjuvant-therapy-with-imatinib-glivec
#12
Kelvin Harvey Kramp, Mohab Galal Omer, Patrick Schoffski, Andre d'Hoore
Gastrointestinal stromal tumours (GISTs) are generally rare but are known to be the most common mesenchymal tumours of the gastrointestinal tract. We present a case of a patient who presented with persistent obstructive gastrointestinal and urological symptoms, a sense of incomplete evacuation and bleeding per rectum. A colonoscopy was performed and a biopsy was taken of a submucosal mass in the distal rectum that revealed a GIST with positive KIT immunostaining. A positron emission tomography (PET)/CT scan showed a large metabolically active distal rectal tumour of 8 cm with macroscopic invasion of surrounding structures...
2015: BMJ Case Reports
https://www.readbyqxmd.com/read/25516839/serum-albumin-and-%C3%AE-1-acid-glycoprotein-impede-the-killing-of-schistosoma-mansoni-by-the-tyrosine-kinase-inhibitor-imatinib
#13
Svenja Beckmann, Thavy Long, Christina Scheld, Rudolf Geyer, Conor R Caffrey, Christoph G Grevelding
In the search for new drugs and drug targets to treat the flatworm disease schistosomiasis, protein kinases (PKs) have come under particular scrutiny because of their essential roles in developmental and physiological processes in schistosome parasites. In this context the application of the anti-cancer Abl tyrosine kinase (TK) inhibitor Imatinib (Gleevec/Glivec; STI-571) to adult Schistosoma mansoni in vitro has indicated negative effects on diverse physiological processes including survival. Motivated by these in vitro findings, we performed in vivo experiments in rodent models of S...
December 2014: International Journal for Parasitology, Drugs and Drug Resistance
https://www.readbyqxmd.com/read/25435999/methylation-analysis-of-the-dapk1-gene-in-imatinib-resistant-chronic-myeloid-leukemia-patients
#14
Selcen Celik, Dilara Akcora, Tulin Ozkan, Nuray Varol, Sena Aydos, Asuman Sunguroglu
Death-associated protein kinase-1 (DAPK1) is a pro-apoptotic gene that induces cellular apoptosis in response to internal and external apoptotic stimulants. The silencing of DAPK1 can result in uncontrolled cell proliferation, indicating that it may have a role in tumor suppression. DAPK1 activity can be inhibited by the cytosine methylation that occurs in its promoter region. These methylation changes in the promoter region of DAPK1 have been reported in a range of solid and hematological malignancies. In the present study, DAPK1 methylation was investigated in chronic myeloid leukemia patients (n=43) using bisulfite conversion followed by methylation-specific polymerase chain reaction...
January 2015: Oncology Letters
https://www.readbyqxmd.com/read/25362813/bioequivalence-study-of-400-and-100-mg-imatinib-film-coated-tablets-in-healthy-volunteers
#15
RANDOMIZED CONTROLLED TRIAL
Andrzej Ostrowicz, Przemysław L Mikołajczak, Marzena Wierzbicka, Piotr Boguradzki
The aim of the study was to investigate the bioavailability of a generic product of 100 mg and 400 mg imatinib film-coated tablets (test) as compared to that of a branded product (reference) at the same strength to determine bioequivalence. The secondary objective of the study was to evaluate tolerability of both products. An open-label, randomized, crossover, two-period, single-dose, comparative study was conducted in 43 (Imatynib-Biofarm 100 mg film-coated tablet) and in 42 (Imatynib-Biofarm 400 mg film-coated tablet), brand name Imatenil, Caucasian healthy volunteers in fed conditions...
September 2014: Acta Poloniae Pharmaceutica
https://www.readbyqxmd.com/read/25215591/cyclin-dependent-kinase-inhibitors-as-marketed-anticancer-drugs-where-are-we-now-a-short-survey
#16
REVIEW
Gaëlle Mariaule, Philippe Belmont
In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons et al., we concentrate our attention on an updated list of compounds under clinical evaluation (phase I/II/III) and discuss their mode of action as ATP-competitive inhibitors...
2014: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/25170123/impact-of-early-molecular-response-in-children-with-chronic-myeloid-leukemia-treated-in-the-french-glivec-phase-4-study
#17
Frédéric Millot, Joelle Guilhot, André Baruchel, Arnaud Petit, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cecile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yakouben, Claudine Schmitt, Virginie Gandemer, Yves Reguerre, Gérard Couillault, Françoise Mechinaud, Jean-Michel Cayuela
Studies in adults have shown that an early molecular response to imatinib predicts clinical outcome in chronic myeloid leukemia (CML). We investigated the impact of the BCR-ABL1 transcript level measured 3 months after starting imatinib in a cohort of 40 children with CML. Children with a BCR-ABL1/ABL ratio higher than 10% at 3 months after the start of imatinib had a larger spleen size and a higher white blood cell count compared with those with BCR-ABL1/ABL ≤10%. Children with BCR-ABL1/ABL ≤10% 3 months after starting imatinib had higher rates of complete cytogenetic response and major molecular response at 12 months compared with those with BCR-ABL1/ABL >10%...
October 9, 2014: Blood
https://www.readbyqxmd.com/read/25110309/-the-glivec%C3%A2-case-the-first-example-of-a-global-debate-on-the-drug-patent-system
#18
Inês Moital, Fèlix Bosch, Magí Farré, Mariano Maddaleno, Josep-E Baños
OBJECTIVE: To describe the sequence of events involving the Glivec® case in India and to analyze the opinions generated in distinct settings. METHOD: We performed a systematic search for articles concerning the imatinib (Glivec®) patent in India. We selected those sources that described the events, decisions of the authorities involved, and press and scientific opinions. Dates and arguments presented by the involved parties were clearly identified. RESULTS: Of 886 documents initially obtained, we selected 40 documents published between 2003 and 2013...
November 2014: Gaceta Sanitaria
https://www.readbyqxmd.com/read/25034734/cultural-factors-related-to-adherence-to-imatinib-in-cml-a-mexican-perspective
#19
Olga Graciela Cantú-Rodríguez, Mónica Sánchez-Cárdenas, César Homero Gutiérrez-Aguirre, José Carlos Jaime-Pérez, Consuelo Mancias-Guerra, Oscar González-Llano, David Gómez-Almaguer
INTRODUCTION: The advent of imatinib as a therapeutic option of chronic myeloid leukemia (CML) has transformed this previously highly resistant disease into one that is susceptible to management with oral drugs that now offer high long-term survival rates. However, achieving an adequate adherence to treatment regimes is of critical importance. The characteristics of treatment compliance in Mexican patients have not been determined. METHODS: We evaluated 38 CML patients, members of the Glivec(®) International Patient Assistance Program (GIPAP)...
March 2015: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/24991604/side-effects-of-antineoplastic-and-immunomodulating-medications-reported-by-european-consumers
#20
Lise Aagaard, Ebba Holme Hansen
OBJECTIVE: To characterize adverse drug reactions (ADRs) reported by European (EU) consumer for antineoplastic and immunomodulating medications. METHODS: ADRs reported by consumers of antineoplastic and immunomodulating medications (anatomical therapeutic chemical [ATC]) group L from 2007 to 2011 and located in the EU ADR database, EudraVigilance, were analyzed. Data were categorized with respect to age and sex, category, and seriousness of reported ADRs and medications...
January 2013: Journal of Research in Pharmacy Practice
keyword
keyword
106206
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"